Influence of rofecoxib on experimental colonic carcinogenesis in rats
- PMID: 15537374
- DOI: 10.4321/s1130-01082004001000002
Influence of rofecoxib on experimental colonic carcinogenesis in rats
Abstract
Aim: To investigate the effect of a selective cyclooxigenase-2 (COX-2) inhibitor, rofecoxib, in the prevalence of experimental colon tumors in rats.
Experimental design: Experimental study with 35 male Sprague-Dawley rats, divided into four groups: a) control group without experimental manipulation (n = 5); b) pharmacological carcinogenesis with 1-2 dimethylhydrazine dihydrocloride (n = 10); c) pharmacological carcinogenesis and addition of acetylsalicylic acid (AAS) (n = 10); and d) carcinogenesis and addition of rofecoxib (n = 10). Carcinogenesis was induced with 1-2 dimethylhydrazine at a weekly dose of 25 mg/kg for 18 weeks. Colon tumors were isolated at 20 weeks. Antiinflammatory agents were given at a dose of AAS 30 mg/kg and rofecoxib at 3 mg/kg.
Results: The percentage of colonic tumors was significantly reduced in the rofecoxib group. This result was found for all tumors and for the malignant lesions, adenocarcinomas.
Conclusions: Rofecoxib, a selective COX-2 inhibitor, reduced the percentage of drug-induced neoplastic glandular tissue in rats.
Comment in
-
Colorectal cancer and Coxibs.Rev Esp Enferm Dig. 2004 Oct;96(10):673-5; 675-7. doi: 10.4321/s1130-01082004001000001. Rev Esp Enferm Dig. 2004. PMID: 15537373 English, Spanish. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
